comparemela.com

Latest Breaking News On - Tellbio inc - Page 1 : comparemela.com

Tellbio's Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230

Tellbio's Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Andover
Davidt-miyamoto
Annie-partisano
Tellbio-technology
Tellbio-inc
Technology-demonstrates
Imaging-biomarkers
Metastatic-castration-resistant-prostate-cancer
Senior-vice-president
Assistant-professor

Ultrasensitive blood test detects 'pan-cancer

<p>In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target=" blank">Mass General Brigham</a>, <a href="https://wyss.harvard.edu/" target=" blank">the Wyss Institute for Biologically Inspired Engineering at Harvard University</a> and <a href="https://www.dana-farber.org/" target=" blank">Dana-Farber Cancer Institute</a>, in collaboration with researchers from across the country and beyond the U.S., researchers developed a low-cost, ultrasensitive blood test to detect minute levels of a cancer biomarker that is highly specific to multiple common cancers. Each test can be performed with merely half a drop of blood (25 microliters). The tool showed promise for early cancer detection and disease monitoring, and could potentially be used in conjunction with other tools for detection, risk stratification and treatment. Results are published in <a href=&quo

Boston
Massachusetts
United-states
Harvard-university
Dana-farber-cancer-institute
Minnesota
American
Mary-ellen-taplin
Brucee-johnson
Li-wang
Omerh-yilmaz
Xiaoyu-yang

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Daniel-haber
Mehmet-toner
David-miyamoto
Shyamala-maheswaran
Annie-partisano
Priteshj-gandhi
Aditya-bardia
Telldx-technology-demonstrates-efficacy-of-novel-drug
Breast-cancer-research-program
Tellbio-inc

Circulating Tumor Cell (CTC) Isolation with TellDx

Single-cell proteomics can elucidate kinase activity in prostate cancer models Kinase activity in bone metastases and epithelial circulating.

Massachusetts
United-states
Priteshj-gandhi
Mehmet-toner
Daniela-haber
Shyamala-maheswaran
Annie-partisano
Cancer-research
Tellbio-inc
Hospital-center
Drs-david-ting
Massachusetts-general-hospital-center

BioSpace Movers & Shakers, May 14

Published: May 13, 2021 By Alex Keown Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis. CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably

Oslo
Norway
Toronto
Ontario
Canada
Texas
United-states
Quadrucept-bio
Vineet-agarwal
Janice-olson
Einaro-vik-mo
Kyle-chiang

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.